Hematology (Amsterdam, Netherlands) · 2025
Effect of metabolic syndrome on prognosis in patients with peripheral T-cell lymphoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Shi-Qi, Li Hong-Bin, Yang Ming-Zhe, Sun Rui-Yang, Zhang Han, Li Li-Ru, Zhao Wen-Hui, Zhang Yue, Zhang Qing-Yuan, Zhao Shu
Аннотация
OBJECTIVES: Peripheral T-cell lymphoma (PTCL) is characterized by significant heterogeneity and poor prognosis, with its high mortality rate remaining an unresolved challenge in clinical treatment. Recent studies have established metabolic syndrome (MetS) as a prognostic factor in various malignancies, yet its association with PTCL remains unexplored. This study aims to evaluate the impact of MetS on the prognosis of PTCL patients.
METHODS: A retrospective analysis was conducted on 122 newly diagnosed PTCL patients. Generation and comparison of survival curves using Kaplan-Meier method and log-rank test, respectively. Cox proportional hazards regression models identified factors associated with overall survival (OS) and progression-free survival (PFS).
RESULTS: Patients with MetS exhibited significantly shorter median OS (25.03 months vs. 50.83 months) and PFS (9.6 months vs. 29.4 months) compared to non-MetS counterparts. MetS was significantly correlated with shorter OS and PFS in both univariate and multivariate regression analyses. Patients with both IPI 3-5 and MetS had the poorest median OS and PFS, whereas those with IPI 0-2 and no MetS demonstrated the longest survival. MetS significantly shortened OS in ALK + ALCL patients (P = 0.009) and PFS in ALK-ALCL patients (P = 0.008).
CONCLUSION: MetS is an independent prognostic factor for both OS and PFS of PTCL patients, showing strong prognostic effect. Combining MetS with IPI enables further stratification of patients, and MetS can strongly supplement the existing prognostic scoring systems in the future.
METHODS: A retrospective analysis was conducted on 122 newly diagnosed PTCL patients. Generation and comparison of survival curves using Kaplan-Meier method and log-rank test, respectively. Cox proportional hazards regression models identified factors associated with overall survival (OS) and progression-free survival (PFS).
RESULTS: Patients with MetS exhibited significantly shorter median OS (25.03 months vs. 50.83 months) and PFS (9.6 months vs. 29.4 months) compared to non-MetS counterparts. MetS was significantly correlated with shorter OS and PFS in both univariate and multivariate regression analyses. Patients with both IPI 3-5 and MetS had the poorest median OS and PFS, whereas those with IPI 0-2 and no MetS demonstrated the longest survival. MetS significantly shortened OS in ALK + ALCL patients (P = 0.009) and PFS in ALK-ALCL patients (P = 0.008).
CONCLUSION: MetS is an independent prognostic factor for both OS and PFS of PTCL patients, showing strong prognostic effect. Combining MetS with IPI enables further stratification of patients, and MetS can strongly supplement the existing prognostic scoring systems in the future.